Last reviewed · How we verify
NCT02918825
Long-acting Paliperidone Palmitate Injection and Olanzapine for Schizophrenia
NA trial testing Olanzapine in Schizophrenia in 100 participants. Completed in 30 September 2017.
30 August 2017
Quick facts
| Lead sponsor | Beijing HuiLongGuan Hospital |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 100 |
| Start date | 1 September 2016 |
| Primary completion | 30 August 2017 |
| Estimated completion | 30 September 2017 |
| Sites | 1 location across China |
Drugs / interventions tested
- Olanzapine (olanzapine) — full drug profile →
- Paliperidone — full drug profile →
Conditions studied
- Schizophrenia — all drugs for Schizophrenia →
Sponsor
Beijing HuiLongGuan Hospital
Who can join
Adults 18 to 45, any sex, with Schizophrenia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A randomized trial of olanzapine and Long-acting paliperidone palmitate injection in the treatment of 100 treatment- naive first-episode patients with schizophrenia.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT02918825
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Olanzapine
Trials testing the same drug.
- NCT07442890 — A Cohort Study on the Prevention of Nausea and Vomiting Induced by Concurrent Chemoradiotherapy for Lung Cancer Using Ro · NA · not yet recruiting
- NCT07482891 — An Exploratory Study on Efficacy and Safety of Fosaprepitant and Palonosetron Hydrochloride for Injection in Preventing · Phase 4 · not yet recruiting
- NCT07208305 — Olanzapine Plus Metoclopramide for the Prevention of Opioid-Induced Nausea and Vomiting · Phase 3 · recruiting
- NCT06995508 — Olanzapine for Managing Anorexia in Head and Neck Cancer Patients Undergoing Chemoradiation, MACRO Trial · Phase 2 · recruiting
- NCT06554613 — Olanzapine Impact on First-line Immunotherapy for Advanced EGFR-negative NSCLC · Phase 2 · not yet recruiting
Other recruiting trials for Schizophrenia
Currently open trials in the same condition.
- NCT07424404 — A Study to Evaluate the Long-term Safety and Tolerability of KarXT and KarX-EC for the Treatment of Schizophrenia and Au · Phase 3 · recruiting
- NCT07467993 — Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia · Phase 2 · recruiting
- NCT07379827 — Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT) · recruiting
- NCT06758414 — CBT-CP for Veterans With SMI · NA · recruiting
- NCT07395206 — Acceptability, Feasibility and Preliminary Outcomes of the Kiso Mind App for Outpatients With Schizophrenia Spectrum Dis · NA · recruiting
Other Beijing HuiLongGuan Hospital trials
Trials by the same sponsor.
- NCT07518264 — Efficacy and Underlying Mechanisms of Group-Based Natural Psychotherapy for Anxiety Disorder · NA · active not recruiting
- NCT07317765 — Research on New Methods and New Models of Rehabilitation Intervention for Cancer Patients Based on Exercise and Psycholo · NA · active not recruiting
- NCT06292156 — tACS Treatment for Cognitive Impairments in Methamphetamine Addicts · NA · completed
- NCT05552014 — Study on the Efficacy Mechanism of Natural Psychotherapy for Neurosis · NA · recruiting
- NCT04055181 — Influence of rTMS on Symptoms and Cognitive Function in Patients With Psychiatric Disorders · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02918825 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Beijing HuiLongGuan Hospital
- Last refreshed: 18 January 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02918825.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing